All News

Meeting audience conference

ACR 2024 - Day 1 Report

d Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
figure sitting in top of hourglass

axSpA: Moving the needle in time to diagnosis

d Antoni Chan, MD, PhD

The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes. Data from the SPACE cohort (abstract 0566), the ASAS-PerSpA study (abstract 0550) and the US Claims data (abstract 0558), allows us to highlight the barriers to early diagnosis of axSpA and identify opportunities for improving early diagnosis and treatment.

Read Article
ACR Best

#ACR 2024 BEST Abstracts from Day 1

d Jack Cush, MD

The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC.  Here are some of the best abstracts from Saturday Nov. 16th.

Read Article
A framework for critical conversations with patients (because the big decisions deserve high quality counselling, otherwise the consequences are real) #ACR24 16S17 @RheumNow https://t.co/fiwYY1DuMq

Links:

David Liew drdavidliew ( View Tweet)
"Do not fear RPF." - John Stone Retroperitoneal fibrosis certainly feels challenging at times, and radiologic features might stay even after functional improvement but we've come a long way (although, despite B cell depletion, there's plenty more to do) #ACR24 16S26 @RheumNow https://t.co/2Y3buXrAFY

Links:

David Liew drdavidliew ( View Tweet)
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it). https://t.co/GZ7tZ6fNMK Great for all US rheumatologists, but also very handy for all of us globally #ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR

Links:

David Liew drdavidliew ( View Tweet)
Abstract 333 showed that in a cohort of patients with IIM-ILD increased age, PH, FVC decline at 1 yr, SOB at 2 years were predictors for mortality and lung transplant ! #ACR24 @RheumNow https://t.co/NgOj7WKeE3

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Factors associated w/ secukinumab response in PsA? Analysis of 2.7k pt in EuroSpA Associated w/ favorable response ❗️elevated CRP >10 mg/L ❗️fewer prev tx Associated w/ lower response: ❗️smoking ❗️higher patient global score / HAQ @RheumNow #ACR24 Abstr 2325

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/DZrM5aQpJ7 https://t.co/CkGP6H8J6x

Links:

Dr. John Cush RheumNow ( View Tweet)
Real shame to see a fair few withdrawn oral presentations on #ACR24 schedule. Surely there is a better way? I'm sure a fellow would have loved to have the opportunity to present their project as an oral, even at short notice. @RheumNow

Richard Conway RichardPAConway ( View Tweet)

Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1 showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA Again, effect of gender differences @RheumNow #ACR24 abs599 https://t.co/2DPYC8exES

Links:

sheila RHEUMarampa ( View Tweet)
New data to guide role of long-term, low dose GC in GPA Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily Fewer relapses on 5mg pred but w/qualifications: 👉 most flares = minor 👉 no difference in flares if RTX on board @RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Come visit @rheumnow where #ACR24 #RheumEducation is distilled and disseminated. @uptoTate https://t.co/vzMeRL8307

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow

Richard Conway RichardPAConway ( View Tweet)

What is my risk of developing SLE? Abstract 0843 highlights a predictive model that accurately classifies SLE risk using genetics, lifestyle, and environmental factors. Model 3 (genetics + environment + lifestyle) performed the best compared to models 1 and 2. @RheumNow #ACR24 https://t.co/sk9oG0OY3W

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx

Links:

Richard Conway RichardPAConway ( View Tweet)
Should we screen new #PMR pts for #LVV? Pts with PMR had lower risk of aortic complications vs #GCA & similar risk as gen pop BUT if they developed GCA later, the risk was same as those with new GCA ➡️Screening recommended in new GCA but not PMR pts Ab0859 #ACR24 @RheumNow https://t.co/HsHPGlt5A9

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
@abdelhamed012 @RheumNow Same https://t.co/uScez6UwBp

Links:

Richard Conway RichardPAConway ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×